Document text
Principal Investigator: Mirella Salvatore
Organization: WEILL MEDICAL COLL OF CORNELL UNIV
Fiscal Year: 2024
Award: $296,625
Funding agency: National Institute of Allergy and Infectious Diseases
ABSTRACT
One of the biggest challenges for the development of Coronavirus Disease 2019 (COVID-19) vaccines and
therapeutics is the emergence of SARS-CoV-2 variants with immune-escape or resistance mutations. Multiple
evidence points to the chronic infection of immunocompromised hosts, especially individuals with hematologic
malignancies, as one of the main mechanisms for the emergence and spread of these variants. While most
people with a competent immune system successfully clear SARS-CoV-2 infection within days, some patients
with hematologic malignancies and weakened immunity get persistently infected for months with virus replicating
often at high titers. As for other RNA viruses, SARS-CoV-2 replication can lead to the rapid accumulation of
mutations over time. Thus, persistent infection of an immunocompromised host provides the timeframe during
which the virus accumulates more genetic mutations than expected from individual infections without the need
of transmission to another host. Moreover, these individuals could remain contagious for longer periods of time
and sustain transmission to the community of variants potentially associated with virus fitness advantages,
including increased transmissibility or resistance to COVID-19 vaccines or treatments. Which host immune
background enables chronic infection, what specific selection acts on the virus, and what effects on the host do
emerging mutations exert over the course of the disease are currently unknown. Moreover, there are no tools
that allow the early identification of subjects that will develop prolonged infection. We hypothesize that specific
defects in B and T cell populations that favor prolonged infection can be leveraged for the development of an
early prediction tool to identify subjects with protracted infection where the virus is accumulating mutations. To
address this, we will integrate patient level and epidemiological data with immune profiling and SARS-CoV-2
deep sequencing to: (1) determine the immune defects linked to prolonged replication or acute disease; (2)
ascertain the effect of different immunosuppressive conditions and therapeutics on SARS-CoV-2 genetic
diversity within the infected host.
Our studies will advance our understanding of the immune mechanisms involved in SARS-CoV2 persistence in
the immunocompromised host and inform the development of optimal therapies and public health interventions
to prevent the emergence and spread of new viral variants. This approach, if successful, is also relevant to other
respiratory viruses.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Acute Disease><Address><Affect><Antibodies><Antibody Response><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Biological><Blood Sample><Blood specimen><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 anti-viral><COVID-19 antiviral><COVID-19 infected patient><COVID-19 infection><COVID-19 patient><COVID-19 positive patient><COVID-19 therapy><COVID-19 transmission><COVID-19 treatment><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus infection><COVID-19 virus transmission><COVID19 infection><COVID19 patient><COVID19 positive patient><COVID19 virus><CV-19><Cancers><Cell Body><Cells><Characteristics><Chronic><Clinical><Clinical Data><CoV-2><CoV2><Communities><Coronavirus Infectious Disease 2019><DNA Alteration><DNA Sequence Alteration><DNA mutation><Data><Defect><Development><Disease><Disease Management><Disease Progression><Disorder><Disorder Management><Early identification><Epidemiological data><Epidemiology><Epidemiology data><Event><Evolution><General Population><General Public><Genetic Alteration><Genetic Change><Genetic Diversity><Genetic Variation><Genetic defect><Genetic mutation><Goals><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Immune><Immune mediated therapy><Immune system><Immunes><Immunity><Immunochemical Immunologic><Immunocompetent><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunologic><Immunologic Subtyping><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunomodulators><Immunophenotyping><Immunosuppressants><Immunosuppressed Host><Immunosuppression><Immunosuppression Effect><Immunosuppressive Agents><Immunosuppressive Effect><Immunosuppressive drug><Immunosuppressive treatment><Immunotherapy><Individual><Infection><Infection Control><Intervention><Intervention Strategies><Link><Malignant Hematologic Neoplasm><Malignant Neoplasms><Malignant Tumor><Methods><Molecular><Mutation><Outcome><Patients><Persons><Phenotype><Play><Population><Preventative measure><Preventive measure><Public Health><RNA Viruses><Research><Resistance><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 anti-viral><SARS-CoV-2 antiviral><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 therapy><SARS-CoV-2 transmission><SARS-CoV-2 treatment><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 anti-viral><SARS-CoV2 antiviral><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SEQ-AN><Sampling><Sequence Alteration><Sequence Analyses><Sequence Analysis><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severities><Severity of illness><Source><Specificity><Steroid Compound><Steroids><Symptoms><T cell response><T-Cells><T-Lymphocyte><Therapeutic><Time><Transmission><Variant><Variation><Viral><Viral Burden><Viral Diseases><Viral Genetics><Viral Load><Viral Load result><Viral reservoir><Virus><Virus Diseases><Virus Replication><Virus reservoir><Wuhan coronavirus><acute COVID-19><acute SARS-CoV-2 infection><acute disease/disorder><acute disorder><acute infection><acute phase of COVID-19><acute phase of SARS-CoV-2 infection><biologic><chronic infection><cohort><communicable disease transmission><coronavirus disease 2019><coronavirus disease 2019 anti-viral><coronavirus disease 2019 antiviral><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 therapy><coronavirus disease 2019 transmission><coronavirus disease 2019 treatment><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease 2019 virus transmission><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 patient><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><data integration><deep sequencing><developmental><disease severity><disease transmission><emergent virus><emerging virus><epidemiologic><epidemiologic data><epidemiological><experience><fitness><genome mutation><genomic alteration><hCoV19><high dimensionality><high risk><hypoimmunity><immune competent><immune deficiency><immune modulators><immune suppression><immune suppressive activity><immune suppressive agent><immune suppressive function><immune suppressor><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunodeficiency><immunophenotype><immunosuppressed patient><immunosuppressive activity><immunosuppressive function><immunosuppressive response><immunosuppressive substance><immunosuppressor><individualized therapeutic><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infectious disease transmission><interventional strategy><malignancy><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><nasopharyngeal swab><neoplasm/cancer><novel><optimal therapies><optimal treatments><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><persistent infection><personalized therapeutic><predictive tools><prevent><preventing><public health intervention><replication therapy><resistance mutation><resistant><resistant mutation><respiratory virus><severe acute respiratory syndrome coronavirus 2 anti-viral><severe acute respiratory syndrome coronavirus 2 antiviral><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 transmission><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><social role><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutically effective><thymus derived lymphocyte><tool><transmission process><transmitted COVID-19><transmitted SARS-CoV-2><transmitted coronavirus disease 2019><transmitted severe acute respiratory syndrome coronavirus 2><treat COVID-19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID><viral emergence><viral genomics><viral infection><viral multiplication><viral replication><virus genetics><virus genomics><virus host interaction><virus infection><virus multiplication><virus-induced disease>